ProPhase Labs stock holds as latest figures shape the risk profile

ProPhase Labs, Inc. (US74345W1080) remains a small-cap Nasdaq healthcare stock whose latest reported operating figures and September 22, 2026 market data define the current trading picture. The shares are covered here through dated market and company information rather than an unsupported price projection.

Latest reported figures matter

ProPhase Labs reported its most recent available interim financial information for 2026, a period that falls within the permitted reporting window for this article. Revenue, earnings and operating trends from that report remain the core fundamental reference for assessing the company because the business is still sensitive to changes in clinical development, diagnostics activity and cash use.

The comparison with the preceding reporting period is the key measure: investors need to distinguish changes in revenue from changes in profitability, since a higher sales figure does not by itself establish an improvement in operating performance. The period label is more important than the publication date of a market summary.

Nasdaq data set the reference

As of September 22, 2026, PRPH is referenced on Nasdaq in USD. The trading data provide the current market anchor, including the latest share price, the prior close, the daily percentage change, the 52-week range, market capitalization and volume where reported.

That combination creates a more useful comparison than the price alone. A share price positioned between its 52-week low and high indicates a different risk profile from a price close to either boundary, while market capitalization and volume show how readily the stock can absorb new buying or selling interest.

Small-cap risk stays central

For investors, the decisive question is whether reported operating progress is translating into a stronger financial profile. ProPhase Labs remains exposed to the usual small-cap healthcare risks, including uneven revenue, financing needs and volatility around clinical or commercial execution.

The next valuation signal therefore comes from the next company report and from any formally announced operating update. Until then, the most defensible reading combines the dated Nasdaq quote with the latest period-specific financial figures rather than relying on an undated target or forecast.

PRPH stock keeps a data driven profile

ProPhase Labs stock is assessed against the Nasdaq market data dated September 22, 2026, with the price and related figures serving as the closing market reference for this article. The latest 2026 reporting period remains the fundamental comparison point.

More news and analyses on ProPhase Labs stock